Assessment of device-related thrombus and associated clinical outcomes with the WATCHMAN left atrial appendage closure device for embolic protection in patients with atrial brillation (from the PROTECT-AF Trial). Am J Cardiol. 2016;117(7):1127-1134. 450. Holmes DR, Doshi SK, Kar S, et al. Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial brillation: a patient-level meta-analysis. J Am Coll Cardiol. 2015;65(24):2614-2623. 451. Holmes DR, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial brillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014;64(1):1-12. 452. Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial brillation: a randomised non- inferiority trial. Lancet. 2009;374(9689):534-542. 453. Masoudi FA, Calkins H, Kavinsky CJ, et al. 2015 ACC/HRS/SCAI left atrial appendage occlusion device societal overview. Heart Rhythm. 2015;12(10):e122-e136. 454. Park JW, Bethencourt A, Sievert H, et al. Left atrial appendage closure with Amplatzer cardiac plug in atrial brillation: initial European experience. Catheter Cardiovasc Interv. 2011;77(5):700- 706. 455. Gloekler S, Shakir S, Doblies J, et al. Early results of rst versus second generation Amplatzer occluders for left atrial appendage closure in patients with atrial brillation. Clin Res Cardiol. 2015;104(8):656-665. 1200 Evidence-Based Medicine [ 1 5 4 # 5 C H E S T N O V E M B E R 2 0 1 8 ] 456. Tereshchenko LG, Henrikson CA, Cigarroa J, Steinberg JS. Comparative effectiveness of interventions for stroke prevention in atrial brillation: a network meta-analysis. J Am Heart Assoc. 2016;5(5). 457. Gianni C, Di Biase L, Trivedi C, et al. Clinical implications of leaks following left atrial appendage ligation with the LARIAT device. JACC Cardiovasc Interv. 2016;9(10):1051-1057. 458. 